BCR and B-cell chronic lymphocytic leukemia: Besides “on-target” and “off-target” activity, there is, at least in CLL, convincing evidence that the anti-tumor effect of ibrutinib is related to the indirect effect that the blockade of the BCR-signaling has on the tumor microenvironment (TME) (4).